TD Vaccine Market: Global Industry Analysis and Forecast (2024-2030)

  • The TD Vaccine Market size was valued at USD 5.5 Bn. in 2023 and the total TD Vaccine Market size is expected to grow at a CAGR of 5.2% from 2024 to 2030, reaching nearly USD 7.84 Bn. by 2030.

  • Format : PDF | Report ID : SMR_1999

TD Vaccine Market Overview

The Td vaccine protects against two diseases that cause serious infections and sometimes be fatal. Tetanus, also known as "lockjaw," is caused by a bacterial toxin that causes painful muscle tightening and is fatal if the breathing muscles are affected. Diphtheria, caused by bacteria that create a thick membrane in the nose and throat, leads to breathing problems and produces a harmful toxin that causes paralysis and heart failure. The TD Vaccine Market is expected to grow at a remarkable CAGR from 2024-2030 because of increasing demand for TD Vaccines for TETANUS (T) and DIPITHERIA (D) applications globally.

 

The market is mostly driven by increasing awareness of the importance of vaccination, joined with government advantages to promote vaccination programs globally. Key companies in the TD vaccine market include pharmaceutical businesses, biotechnology businesses, and government activities involved in healthcare. Reasons such as improvements in vaccine technology, growing healthcare expenses, and increasing healthcare infrastructure in developing countries contribute to market growth. The report provides insights into the lucrative opportunities in the TD Vaccine Market at the country level, including cost, segments, trends, region, and commercial development of major global players.

TD Vaccine Market

 

To get more Insights: Request Free Sample Report

 

TD Vaccine Market Dynamics:

The COVID-19 pandemic has heightened health concerns and emphasized preventative healthcare, driving the TD (Tetanus and Diphtheria) vaccine market. Increased awareness of infectious diseases and vaccination's importance has led to increased research, development, and funding in the broader vaccine landscape. The TD vaccine market is experiencing a surge in demand, innovation, and collaborative initiatives to ensure widespread access and protection against these preventable diseases.

 

Public awareness campaigns and information dissemination through media channels foster a proactive approach to healthcare, driving individuals to seek and participate in vaccination programs. This heightened awareness boosts vaccine acceptance and encourages policymakers to prioritize and invest in comprehensive immunization initiatives. As the TD vaccine market increases momentum, it reflects the positive impact of informed public engagement on health outcomes, driving the TD vaccine market size.

 

  • There are 11 vaccines presented for use in the United States to aid against diphtheria and tetanus. 9 of these vaccines also help protect against whooping cough.

TD Vaccine Market1

The TD vaccine market aspects several restraints, hampering its growth potential. Regulatory hurdles and approval procedures delay market entry for new vaccines. Also, limited accessibility and affordability in certain regions pose challenges, especially in low-income countries where healthcare infrastructure is underdeveloped. Vaccine hesitancy and misinformation contribute to lower adoption rates, impacting market growth. Resource chain disruptions and manufacturing restraints, mainly through global health crises, lead to shortages and distribution challenges. Also, the development of alternative preventive procedures or contending vaccine technologies distracts attention and resources present from TD vaccines. These factors collectively hinder the market's growth trajectory and necessitate strategic approaches to overcome them.

 

The TD vaccine market faces challenges such as regulatory complexities, vaccine hesitancy because of misinformation and safety concerns, supply chain disruptions, and the emergence of new infectious diseases. Technological advancements are driving the market through innovative research, development, and production methods. Advancements in vaccine technology, such as mRNA platforms, have made vaccine development faster and more efficient. Advanced manufacturing processes improve scalability and reduce production timelines, while cutting-edge technologies enable customization for specific demographics or emerging strains. Digital tools for distribution and monitoring enhance supply chain efficiency. These developments make the TD vaccine market more flexible, responsive, and better placed to meet health challenges.

 

TD Vaccine Market Segment Analysis:

Based on Application, The TD vaccine market segment consists of tetanus (T) and dipitheria (D). Tetanus is the most profitable category because of its effective prevention of a potentially fatal bacterial infection. This is because of its importance in comprehensive immunization strategies and widespread adoption. The T application's dominant market share is attributed to its focus on preventing tetanus and established vaccination protocols. Diphtheria, on the other hand, is experiencing the highest Compound Annual Growth Rate (CAGR) because of increased awareness and emphasis on preventing diphtheria-related health risks. This growth is attributed to ongoing research and evolving vaccination strategies, reflecting a proactive response to emerging health challenges in the TD vaccine landscape.

TD Vaccine Market2

TD Vaccine Market Regional Insight:

In North America, The TD (Tetanus and Diphtheria) vaccine industry is dominated in 2023, because of its strong healthcare system, high vaccination rates, and widespread awareness. Widespread vaccination acceptance is aided by the region's dedication to preventative healthcare and well-established immunization practices. North America's leadership in the TD vaccine industry is further enhanced by regulatory backing, R&D investments, and a proactive approach to public health concerns. These factors demonstrate an extensive and efficient response to preventable diseases.

TD Vaccine Market3

The Europe TD Vaccine market is the second-largest because of advanced healthcare systems, strong regulatory frameworks, and robust immunization infrastructure. Collaboration between governments, healthcare institutions, and pharmaceutical companies enhances vaccine accessibility and effectiveness. The German TD Vaccine market holds the largest share, while the UK TD Vaccine market is the fastest-growing in the European region.

 

TD Vaccine Market Competitive Landscape:

  • In 2024, the malaria vaccine, developed through collaboration between the Jenner Institute at Oxford University and the Serum Institute of India leveraging Novavax’s saponin-based adjuvant technology, received support from the European and Developing Countries Clinical Trials Partnership (EDCTP), the Wellcome Trust, and the European Investment Bank (EIB). To date, the Serum Institute of India has manufactured 25 million doses with a capacity to scale up to 100 million doses annually.

 

  • March 4, 2024 – Valneva SE a specialty vaccine company, announced that its senior management is participating at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach is present Valneva at the TD Cowen 44th Annual Health Care Conference, taking place March 4 – 6, 2024, in Boston, MA. Mr. Lingelbach and CFO Peter Bühler are also meeting with institutional investors during the Van Lanschot Kempen Life Sciences Conference, in Amsterdam, The Netherlands.

TD Vaccine Market Scope

Market Size in 2023

USD 5.5 Bn.

Market Size in 2030

USD 7.84 Bn.

CAGR (2024-2030)

5.2 %

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

   Segments

By Type

3-dose Series

More than 3-dose Series

By Application

TETANUS (T)

DIPITHERIA (D)

Regional Scope

North America- United States, Canada, and Mexico

Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America

 

Key Player in the TD Vaccine Market

  1. MASSBIOLOGICS - USA
  2. GSK (GlaxoSmithKline) - United Kingdom
  3. PANACEA BIOTEC LTD. - India
  4. KM BIOLOGICS CO., LTD. - South Korea
  5. MERCK - USA
  6. SANOFI - France
  7. SERUM INSTITUTE OF INDIA PVT. LTD - India
  8. BIONET-ASIA - South Korea
  9. Incepta Pharma - Bangladesh
  10. BB-NCIPD Ltd - Bulgaria
  11. Bharat Biotech - India
  12. Pfizer - USA
  13. emergent biosolutions - USA
  14. AstraZeneca - UK (United Kingdom)
  15. SINOVAC - China
  16. Bavarian Nordic - Denmark
  17. Valneva - France
  18. Dano. Vaccines & Biologicals Private Limited - India
  19. Biological E - India
  20. Moderna - USA
  21. XX.inc


Frequently Asked Questions

The forecast period of the market is 2024 to 2030.

1.    TD Vaccine Market: Research Methodology 
2.    TD Vaccine Market: Executive Summary
3.    TD Vaccine Market: Competitive Landscape
4.    Potential Areas for Investment

4.1. Stellar Competition Matrix
4.2. Competitive Landscape
4.3. Key Players Benchmarking
4.4. Market Structure
4.4.1.    Market Leaders 
4.4.2.    Market Followers
4.4.3.    Emerging Players

4.5. Consolidation of the Market
4.6. Import and export of TD Vaccine Market 
5.    TD Vaccine Market : Dynamics
5.1. Market Driver 
5.1.1.    Increasing Consumer Awareness
5.1.2.    Innovation in Product Offerings

5.2. Market Trends by Region
5.2.1.    North America
5.2.2.    Europe
5.2.3.    Asia Pacific
5.2.4.    Middle East and Africa
5.2.5.    South America

5.3. Market Drivers by Region
5.3.1.    North America
5.3.2.    Europe
5.3.3.    Asia Pacific
5.3.4.    Middle East and Africa
5.3.5.    South America

5.4. Market Restraints
5.5. Market Opportunities
5.6. Market Challenges
5.7. PORTER’s Five Forces Analysis
5.8. PESTLE Analysis
5.9. Strategies for New Entrants to Penetrate the Market
5.10. Regulatory Landscape by Region
5.10.1.    North America
5.10.2.    Europe
5.10.3.    Asia Pacific
5.10.4.    Middle East and Africa
5.10.5.    South America

6.    TD Vaccine Market Size and Forecast by Segments (by value Units)
6.1. TD Vaccine Market Size and Forecast, by Type (2023-2030)
6.1.1.    3-dose Series
6.1.2.    More than 3-dose Series

6.2. TD Vaccine Market Size and Forecast, by Application (2023-2030)
6.2.1.    TETANUS (T)
6.2.2.    DIPITHERIA (D)

6.3. TD Vaccine Market Size and Forecast, by Region (2023-2030)
6.3.1.    North America
6.3.2.    Europe
6.3.3.    Asia Pacific
6.3.4.    Middle East and Africa
6.3.5.    South America

7.    North America TD Vaccine Market Size and Forecast (by value Units)
7.1. North America TD Vaccine Market Size and Forecast, by Type (2023-2030)
7.1.1.    3-dose Series
7.1.2.    More than 3-dose Series

7.2. North America TD Vaccine Market Size and Forecast, by Application (2023-2030)
7.2.1.    TETANUS (T)
7.2.2.    DIPITHERIA (D)

7.3. North America TD Vaccine Market Size and Forecast, by Country (2023-2030)
7.3.1.    United States
7.3.2.    Canada
7.3.3.    Mexico

8.    Europe TD Vaccine Market Size and Forecast (by Value Units)
8.1. Europe TD Vaccine Market Size and Forecast, by Type (2023-2030)
8.1.1.    3-dose Series
8.1.2.    More than 3-dose Series

8.2. Europe TD Vaccine Market Size and Forecast, by Application (2023-2030)
8.2.1.    TETANUS (T)
8.2.2.    DIPITHERIA (D)

8.3. Europe TD Vaccine Market Size and Forecast, by Country (2023-2030)
8.3.1.    UK
8.3.2.    France
8.3.3.    Germany
8.3.4.    Italy
8.3.5.    Spain
8.3.6.    Sweden
8.3.7.    Austria
8.3.8.    Rest of Europe

9.    Asia Pacific TD Vaccine Market Size and Forecast (by Value Units)
9.1. Asia Pacific TD Vaccine Market Size and Forecast, by Type (2023-2030)
9.1.1.    3-dose Series
9.1.2.    More than 3-dose Series

9.2. Asia Pacific TD Vaccine Market Size and Forecast, by Application (2023-2030)
9.2.1.    TETANUS (T)
9.2.2.    DIPITHERIA (D)

9.3. Asia Pacific TD Vaccine Market Size and Forecast, by Country (2023-2030)
9.3.1.    China
9.3.2.    S Korea
9.3.3.    Japan
9.3.4.    India
9.3.5.    Australia
9.3.6.    Asean
9.3.7.    Rest of Asia Pacific

10.    Middle East and Africa TD Vaccine Market Size and Forecast (by Value Units)
10.1. Middle East and Africa TD Vaccine Market Size and Forecast, by Type (2023-2030)
10.1.1.    3-dose Series
10.1.2.    More than 3-dose Series

10.2. Middle East and Africa TD Vaccine Market Size and Forecast, by Application (2023-2030)
10.2.1.    TETANUS (T)
10.2.2.    DIPITHERIA (D)

10.3. Middle East and Africa TD Vaccine Market Size and Forecast, by Country (2023-2030)
10.3.1.    South Africa
10.3.2.    GCC
10.3.3.    Rest of ME&A

11.    South America TD Vaccine Market Size and Forecast (by Value Units)
11.1. South America TD Vaccine Market Size and Forecast, by Type (2023-2030)
11.1.1.    3-dose Series
11.1.2.    More than 3-dose Series

11.2. South America TD Vaccine Market Size and Forecast, by Application  (2023-2030)
11.2.1.    TETANUS (T)
11.2.2.    DIPITHERIA (D)

11.3. South America TD Vaccine Market Size and Forecast, by Country (2023-2030)
11.3.1.    Brazil
11.3.2.    Argentina
11.3.3.    Rest of South America

12.    Company Profile: Key players
12.1.   MASSBIOLOGICS                     
12.1.1.    Company Overview
12.1.2.    Financial Overview
12.1.3.    Business Portfolio
12.1.4.    SWOT Analysis
12.1.5.    Business Strategy 
12.1.6.    Recent Developments

12.2. GSK
12.3. PANACEA BIOTEC LTD.
12.4. KM BIOLOGICS CO., LTD.
12.5. MERCK 
12.6. SANOFI
12.7. SERUM INSTITUTE OF INDIA PVT. LTD
12.8. BIONET-ASIA
12.9. Incepta Pharma
12.10. BB-NCIPD Ltd
12.11. Bharat Biotech
12.12. Pfizer
12.13. emergent biosolutions
12.14. AstraZeneca
12.15. SINOVAC
12.16. Bavarian Nordic
12.17. Valneva
12.18. Dano. Vaccines & Biologicals Private Limited
12.19. Biological E
12.20. Moderna
12.21. XX.inc
13.    Key Findings
14.    Industry Recommendation

Enquiry Before Buy


Request Sample PDF